Vanda Pinto, PhD, science writer —

​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

Kyowa Kirin Stops KW-6356 Program Despite Promising Results

Kyowa Kirin has discontinued the clinical development of its investigational treatment, KW-6356, for Parkinson’s disease, despite Phase 2 clinical trial data showing promising results as a monotherapy or in combination with levodopa. The decision was based on the “global regulatory landscape, development hurdles, and timelines for potential market…

Biogen and Alectos Team Up to Advance AL01811 for Parkinson’s

Biogen and Alectos Therapeutics have signed an exclusive license and collaboration agreement to further develop and commercialize AL01811, a small molecule therapy, as a potential treatment for Parkinson’s disease. “Through this collaboration with Alectos, we hope to improve the lives of people living with Parkinson’s disease by advancing…

Parkinson’s and Essential Tremor Share ‘Central Origin,’ Study Suggests

Accidental falls and co-existing conditions, or comorbidities, like fatigue, depression, and sleeping problems are frequent in older adults with either Parkinson’s disease or essential tremor syndrome, suggesting “similar central origins” for these two disorders, a study reported. Its data also support essential tremor being found in older Parkinson’s patients, and Parkinson’s in those…

New MyoCycle Models on Market After MYOLYN Wins FDA Clearance

The second version of the MyoCycle, a functional electrical stimulation (FES) bike designed for people with motor disabilities, including Parkinson’s disease, is now available in the U.S. after winning the needed go-ahead from federal regulators. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to developer…

FDA Approves Advanced Image Guided Software Program for DBS

Boston Scientific has received approval from the U.S. Food and Drug Administration (FDA) for its Vercise Neural Navigator with STIMVIEW XT, a visualization software that allows doctors to see in real-time the location of leads, or electrodes, within the brain of a Parkinson’s disease patient undergoing deep brain stimulation…

Nitrase Therapeutics Wins MJFF Grant To Study Possible Biomarker

Nitrase Therapeutics has received a second grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the company’s research on nitrated alpha-synuclein, a new potential biomarker to help predict and diagnose Parkinson’s disease. “MJFF is the leading research accelerator for Parkinson’s disease treatments, and…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums